Replies to post #433825 on Amarin Corp Plc (AMRN)

[rosemountbomber]

Chromosome,

The reason the did a 20:1 reverse split in my opinion is they wanted to be comfortably above $5 which is minimum price lot of buy-side shops need to add shares.

For sure. Not saying this will absolutely happen (although it happens in over 90% of RS cases) but always a chance the stock drops before, on, after RS day. Hopefully the worst case scenario is that it drops below the $5 threshold you mention, but not below $1 necessitating this whole charade all over again. I feel confident (as confident as can be with Amarin) that won't happen. So you are correct that Amarin realizes that dynamic. The following is not really related to your post but I am afraid I may be running out of posts today. Sorry.

A poster asked why no questions about the "new formulation". Well, I scanned the transcript and there was no mention of it by Amarin so that is probably a good reason why that question was not asked.

Also I would not get too excited about this GLP-1 thing, as some here may have. The data to be presented is primarily if not entirely concerning antioxidant activity of EPA with respect to Lp(a) and endothelial cells in combo with GLP-1 agonists. That is far from data showing actual results wrt death, strokes, etc. It obviously could mean such benefits, but right now we have data for the last 5 years showing a huge reduction in CVD effects, and our sales are dropping. So I wouldn't get too excited about this yet.

I would like to hear from others who were in the camp of hoping to bail at $4 or $5 in the future. Do you guys think that after this RS we would ever see the stock at $80 or $100? That is what we would need to get our 4 or 5 target. Otherwise the only other thing would be to make so much money on other stocks so as to be able to use up these Amarin losses. Otherwise deduction only $3K every year on the 1040, I would not live long enough to use up even a tiny fraction of the losses.

[ziploc_1]

Chromosome...Also, BP's would have a tough time explaining to their BP investors why they were interested in buying Amarin ...No matter how excellent the company's potential is...a stock price of less than a buck does not exude respect....the BP's would have a tough time explaining that it was an excellent deal.

[Whalatane]

Re what others think ?
Did anyone read the financials ?

U.S. net product revenue was $44.2 million for the three months ended December 31, 2024 compared to $64.9 million in the corresponding period of 2023.

European net product revenue was $4.0 million for the three months ended December 31, 2024 compared to $1.5 million in the corresponding period of 2023.

Rest of World (RoW) net product revenue was $11.9 million for the three months ended December 31, 2024 compared to $4.2 million in the corresponding period of 2023.

Revenue declining sharply in the US with meager gains in the EU /UK and much of ROW being from selling product for launch's .

Glad I bailed on this when the CFO left .......ALWAYS sell when a CFO leaves to pursue other opportunities . He certainly didn't want to be around for this .
Good luck to those who still hold . Wish it had turned out better .
Kiwi

[couldbebetter]

Chromosome, The time to buy AMRN is when
Denner/Sarissa acquires more shares, and/or
when AMRN initiates a share buyback. The
problem with revenues is that only a BP can
really move the needle. So far, Denner has not
found a BP to acquire AMRN. Will he be able
to find a buyer before it is too late? Maybe
Denner can interest a BP with the New Formulation.
If the New Formulation has any value to BP I would
prefer to have a BP develop and run with it rather
than have AMRN attempt another GIA disaster.